Autopsy report · NCT01348126
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Cause of deathNo reason given
Life of this trial
- Ran for about 4 years 5 months before it stopped.
- 385 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Synta Pharmaceuticals Corp.
- Sponsor type
- Industry
- Conditions
- Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Metastatic
- Interventions
- Docetaxel; Combination of ganetespib and docetaxel
- Participants
- 385
- Sites
- 53
- Countries
- Belgium, Bosnia and Herzegovina, Canada, Croatia, Czechia, Germany, Poland, Romania, Russia, Serbia, Spain, United Kingdom and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.